What is the current valuation of the ophthalmic topical-therapeutics market in South Korea?

The market valuation was $473.31 Million in 2024. Read More

What is the projected market size for the ophthalmic topical-therapeutics market by 2035?

The market is expected to reach $1022.34 Million by 2035. Read More

What is the expected CAGR for the ophthalmic topical-therapeutics market during the forecast period 2025 - 2035?

The expected CAGR is 7.25% during the forecast period. Read More

Which product type segment had the highest valuation in 2024?

The 'Others' segment in product type had a valuation of $168.65 Million in 2024. Read More

What are the key players in the South Korean ophthalmic topical-therapeutics market?

Key players include Allergan, Novartis, Bausch Health, Santen Pharmaceutical, Regeneron Pharmaceuticals, Hoya Corporation, Merck & Co., and Pfizer. Read More

Which disease type segment is projected to grow the most by 2035?

The 'Glaucoma' segment is projected to grow from $120.0 Million to $250.0 Million by 2035. Read More

What dosage form segment is expected to have the highest valuation in 2035?

The 'Eye Drops' segment is expected to reach $410.0 Million by 2035. Read More

How does the distribution channel of drug stores compare to online pharmacies in 2024?

In 2024, drug stores had a valuation of $150.0 Million, while online pharmacies were valued at $80.0 Million. Read More

What is the valuation of the anti-inflammatory segment in 2024?

The anti-inflammatory segment had a valuation of $47.0 Million in 2024. Read More

What is the expected growth for the artificial tears segment by 2035?

The artificial tears segment is projected to grow from $94.66 Million to $204.0 Million by 2035. Read More

South Korea Ophthalmic Topical Therapeutics Market

ID: MRFR/HC/50784-HCR

200 Pages

Nidhi Mandole

Last Updated: March 02, 2026

South Korea Ophthalmic Topical Therapeutics Market Research Report By Product Type (Artificial Tears, Anti-allergy, Antibiotic Drops, Anti-Inflammatory, Antiglaucoma, Others), By Disease Type (Dry Eye, Eye Allergy, Glaucoma, Eye Infection, Retinal Disorders, Uveitis, Others), By Dosage Form (Eye Drops, Gels, Ointments, Others) and By Distribution Channel (Hospital Pharmacies, Drug Stores, Online Pharmacies, Others) - Growth & Industry Forecast 2025 To 2035

South Korea Ophthalmic Topical Therapeutics Market Infographic

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Pharmaceutical, BY Product Type (USD Million)
  1. 4.1.1 Artificial Tears
  2. 4.1.2 Anti-allergy
  3. 4.1.3 Antibiotic Drops
  4. 4.1.4 Anti-inflammatory
  5. 4.1.5 Antiglaucoma
  6. 4.1.6 Others
2. 4.2 Pharmaceutical, BY Disease Type (USD Million)
  1. 4.2.1 Dry Eye
  2. 4.2.2 Eye Allergy
  3. 4.2.3 Glaucoma
  4. 4.2.4 Eye Infection
  5. 4.2.5 Retinal Disorders
  6. 4.2.6 Uveitis
  7. 4.2.7 Others
3. 4.3 Pharmaceutical, BY Dosage Form (USD Million)
  1. 4.3.1 Eye Drops
  2. 4.3.2 Gels
  3. 4.3.3 Ointments
  4. 4.3.4 Others
4. 4.4 Pharmaceutical, BY Distribution Channel (USD Million)
  1. 4.4.1 Hospital Pharmacies
  2. 4.4.2 Drug Stores
  3. 4.4.3 Online Pharmacies
  4. 4.4.4 Others
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Pharmaceutical
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Pharmaceutical
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Allergan (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Novartis (CH)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Bausch Health (CA)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Santen Pharmaceutical (JP)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Regeneron Pharmaceuticals (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Hoya Corporation (JP)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Merck & Co. (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Pfizer (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 SOUTH KOREA MARKET ANALYSIS BY PRODUCT TYPE
3. 6.3 SOUTH KOREA MARKET ANALYSIS BY DISEASE TYPE
4. 6.4 SOUTH KOREA MARKET ANALYSIS BY DOSAGE FORM
5. 6.5 SOUTH KOREA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
6. 6.6 KEY BUYING CRITERIA OF PHARMACEUTICAL
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF PHARMACEUTICAL
9. 6.9 DRIVERS IMPACT ANALYSIS: PHARMACEUTICAL
10. 6.10 RESTRAINTS IMPACT ANALYSIS: PHARMACEUTICAL
11. 6.11 SUPPLY / VALUE CHAIN: PHARMACEUTICAL
12. 6.12 PHARMACEUTICAL, BY PRODUCT TYPE, 2024 (% SHARE)
13. 6.13 PHARMACEUTICAL, BY PRODUCT TYPE, 2024 TO 2035 (USD Million)
14. 6.14 PHARMACEUTICAL, BY DISEASE TYPE, 2024 (% SHARE)
15. 6.15 PHARMACEUTICAL, BY DISEASE TYPE, 2024 TO 2035 (USD Million)
16. 6.16 PHARMACEUTICAL, BY DOSAGE FORM, 2024 (% SHARE)
17. 6.17 PHARMACEUTICAL, BY DOSAGE FORM, 2024 TO 2035 (USD Million)
18. 6.18 PHARMACEUTICAL, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
19. 6.19 PHARMACEUTICAL, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 South Korea MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY PRODUCT TYPE, 2025-2035 (USD Million)
  2. 7.2.2 BY DISEASE TYPE, 2025-2035 (USD Million)
  3. 7.2.3 BY DOSAGE FORM, 2025-2035 (USD Million)
  4. 7.2.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

South Korea Pharmaceutical Market Segmentation

Pharmaceutical By Product Type (USD Million, 2025-2035)

Artificial Tears
Anti-allergy
Antibiotic Drops
Anti-inflammatory
Antiglaucoma
Others

Pharmaceutical By Disease Type (USD Million, 2025-2035)

Dry Eye
Eye Allergy
Glaucoma
Eye Infection
Retinal Disorders
Uveitis
Others

Pharmaceutical By Dosage Form (USD Million, 2025-2035)

Eye Drops
Gels
Ointments
Others

Pharmaceutical By Distribution Channel (USD Million, 2025-2035)

Hospital Pharmacies
Drug Stores
Online Pharmacies
Others

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”